Yangtze River Pharmaceutical Group and Shanghai Haiyan Pharmaceutical Technology have divulged new morpholine derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists and reported to be useful for the treatment of cancer, pain, cough, depression, anxiety and genitourinary, gastrointestinal and immunological disorders, among other disorders.